United States Patent 4,886,808: Granisetron Scope, Claims, Expiration, and Patent Landscape
U.S. Patent No. 4,886,808 covers a broad class of indazole-3-carboxamides containing an endo-9-azabicyclo[3.3.1]nonane or related bicyclic amine. Its commercially important compound is granisetron, specifically N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methylindazole-3-carboxamide hydrochloride. The patent issued December 12, 1989 and expired December 12, 2006 under the pre-URAA 17-year-from-issuance term applicable to the patent. The patent no longer creates a U.S. blocking right for generic granisetron.
The patent protected the active molecule, selected salts, pharmaceutical compositions, and therapeutic use in migraine, cluster headache, trigeminal neuralgia, emesis, anxiety, and psychosis. Its commercial importance was concentrated in the antiemetic use of granisetron, later marketed as Kytril.
What drug does U.S. Patent 4,886,808 protect?
U.S. Patent 4,886,808 protects granisetron and structurally related indazole carboxamides. The patent’s key commercial embodiment is:
- Active ingredient: granisetron
- Chemical identity: N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methylindazole-3-carboxamide
- Commercial salt: granisetron hydrochloride
- Pharmacological class: selective 5-HT3 receptor antagonist
- Principal approved use: prevention of nausea and vomiting associated with cancer chemotherapy, radiotherapy, and surgery
Claim 10 expressly identifies the monohydrochloride salt of the 1-methyl indazole compound. That claim is the closest claim to the active ingredient used in Kytril.
The patent is titled “Indazole derivatives.” It was assigned to the predecessor organizations associated with SmithKline Beecham, later part of GlaxoSmithKline. Roche commercialized granisetron as Kytril in major markets. The patent itself establishes the compound and use rights, but it does not by itself establish the terms of any separate commercial licensing arrangement.
What is the chemical scope of claim 1?
Claim 1 is a Markush compound claim. It covers a large genus defined by several variable structural elements.
| Claim element |
Scope |
| Core |
Indazole or related bicyclic aromatic system represented by formula I |
| X |
Carbonyl, CO |
| Y |
NH |
| Z |
NR3 |
| R3 |
Hydrogen, C1-C6 alkyl, selected alkenylmethyl, phenyl, or substituted phenylalkyl |
| R1 |
Hydrogen, halogen, alkyl, alkoxy, alkylthio, acyl, amino, sulfonamide and related substituents |
| R2 |
Substituted azabicyclic amine side chain |
| n |
2 or 3 |
| R4 |
Alkyl, cycloalkyl, substituted heteroarylalkyl, or substituted phenylalkyl |
| Stereochemistry |
Endo configuration is separately claimed |
| Salt status |
Pharmaceutically acceptable salts are included |
The claim requires a carboxamide linkage between the indazole ring and the bicyclic amine. It is therefore directed to a defined chemical architecture, rather than to all 5-HT3 antagonists or all antiemetic compounds.
The R1 and R4 definitions substantially expand the genus. R1 permits substitution at the indazole ring with halogen, trifluoromethyl, alkoxy, alkyl, hydroxy, nitro, amino, sulfonamide, acylamino and related groups. R4 permits hydrophobic and heteroaryl substituents on the bicyclic nitrogen framework.
Claim 1 also covers acceptable pharmaceutical salts. A generic product containing granisetron hydrochloride would fall within the claim if the underlying granisetron structure and claimed stereochemical configuration were present.
How do dependent claims narrow the patent?
The dependent claims progressively identify the commercially relevant structure.
| Claim |
Limitation |
Commercial significance |
| 2 |
n is 3 |
Selects the [3.3.1]nonane-type bicyclic system |
| 3 |
R3 is hydrogen or methyl |
Includes the N-methyl structure of granisetron |
| 4 |
Side chain attached at position 3 |
Defines the principal indazole-3-carboxamide arrangement |
| 5 |
R1 is hydrogen or 5-halo |
Covers unsubstituted and 5-halogenated analogues |
| 6 |
R4 is C1-C7 alkyl |
Narrows the bicyclic nitrogen substituent |
| 7 |
R4 is methyl |
Selects the 9-methyl compound |
| 8 |
Lists six named compounds |
Identifies specific examples, including granisetron |
| 9 |
Y-R2 is endo |
Protects the active stereochemical configuration |
| 10 |
Granisetron monohydrochloride |
Direct salt claim to the commercial product |
Claim 8 lists:
- Unsubstituted indazole compound;
- 5-fluoro analogue;
- 5-chloro analogue;
- 1-methyl compound;
- 1-ethyl compound; and
- Their pharmaceutically acceptable salts.
The fourth listed compound is granisetron. Claim 10 then separately claims its monohydrochloride.
What is the scope of the composition and method claims?
Claims 11 through 20 extend protection beyond the chemical compound.
Pharmaceutical composition claims
Claims 11, 12, 13, 19 and 20 cover pharmaceutical compositions containing a claimed compound and a pharmaceutically acceptable carrier for:
- Migraine or cluster headache;
- Trigeminal neuralgia;
- Emesis;
- Anxiety; and
- Psychosis.
These are use-limited composition claims. They require both the claimed compound and a therapeutic composition directed to the specified condition.
Method-of-treatment claims
Claims 14 through 18 cover administration methods in mammals:
- Claims 14 and 15 cover treatment or prophylaxis of migraine, cluster headache and trigeminal neuralgia.
- Claim 16 covers treatment or prophylaxis of emesis.
- Claim 17 covers treatment of anxiety.
- Claim 18 covers treatment of psychosis.
The method claims are narrower in operation than the compound claim because infringement requires use for the recited therapeutic purpose. They could have been relevant to a branded product or a labeled generic indication during the patent term. They are no longer enforceable because the patent expired.
The patent does not claim every possible route of administration, dosage strength, tablet coating, injectable vehicle, or release profile as an independent formulation technology. Its composition claims require a claimed active compound plus a pharmaceutically acceptable carrier.
When did U.S. Patent 4,886,808 expire?
| Event |
Date or period |
| Patent issued |
December 12, 1989 |
| Applicable term |
17 years from issue for this pre-URAA patent |
| Expected expiration |
December 12, 2006 |
| Current status |
Expired |
| Current blocking effect |
None for U.S. commercial manufacture, sale, or ANDA approval |
The patent was filed and issued under the older U.S. patent-term regime. The 20-year term measured from the earliest effective nonprovisional filing date generally applies to later-filed patents, but does not govern this patent in the same way. No current patent-term extension or pediatric extension is generally associated with the original compound patent.
Patent expiration removed the principal composition and use barrier for generic granisetron. Expiration did not eliminate regulatory requirements, manufacturing controls, trademark rights, or any later patents covering separate formulations or processes.
What was the FDA regulatory status of granisetron?
The FDA approved granisetron hydrochloride as Kytril for prevention of nausea and vomiting associated with emetogenic cancer therapy. Granisetron was approved in tablet and injectable forms, with additional U.S. labeling for postoperative nausea and vomiting depending on the product and approval history.[2]
The FDA approval pathway was an NDA for the innovator product, followed by ANDA approvals for generic granisetron products after the relevant patent and regulatory barriers had been addressed.
| Regulatory issue |
Status |
| Active ingredient |
Granisetron hydrochloride |
| Innovator product |
Kytril |
| Regulatory pathway |
NDA |
| Generic pathway |
ANDA |
| Small-molecule status |
Yes |
| Biosimilar pathway |
Not applicable |
| Current market access |
Generic competition permitted after patent expiry |
Granisetron is a chemically synthesized small molecule. Biosimilar litigation, reference-product exclusivity under the Biologics Price Competition and Innovation Act, and biologic interchangeability rules do not apply.
What was the Orange Book status of U.S. Patent 4,886,808?
The original compound patent was relevant to the Orange Book period for Kytril and granisetron hydrochloride. It is now expired and cannot support a current Paragraph IV enforcement action.
Orange Book analysis must distinguish among:
- The original compound patent;
- Later formulation or dosage-form patents;
- Method-of-use patents;
- Regulatory exclusivity; and
- Trademark protection for Kytril.
The expiration of U.S. Patent 4,886,808 does not automatically establish that every later patent associated with a granisetron product has expired. It does establish that a later applicant cannot be blocked solely by this patent.
The FDA Orange Book lists patents and exclusivity information associated with approved drug products, but does not determine the ultimate validity or enforceability of a patent. Patent listing disputes and the scope of any use code are separate legal issues.[3]
Were there Paragraph IV challenges to U.S. Patent 4,886,808?
Paragraph IV certifications would have been relevant while the patent was listed and unexpired. An ANDA applicant could certify that the patent was invalid, unenforceable, or would not be infringed. A Paragraph IV notice could have triggered patent litigation and, if timely filed, a 30-month stay of approval under the Hatch-Waxman statute.
After December 12, 2006, the patent could no longer provide a live patent-infringement basis for delaying ANDA approval. A current generic applicant would generally rely on a Paragraph III certification for an unexpired listed patent only if another patent remained relevant. For the expired ’808 patent, no present Paragraph IV controversy can maintain a 30-month stay.
Publicly reported litigation surrounding later generic granisetron approvals would need to be separated from litigation involving the ’808 patent itself. A generic challenge to a later formulation patent would not establish a challenge to the original compound patent.
How strong was the patent estate for granisetron?
During its life, the estate was strong because the patent combined several layers of protection in one document:
- Broad genus claim 1;
- Narrower structural claims;
- Specific named compounds;
- Endo stereochemical protection;
- Granisetron hydrochloride claim 10;
- Composition claims;
- Multiple therapeutic-use claims.
The strongest commercial claim was claim 10 because it directly identified the monohydrochloride salt of granisetron. Claims 1 and 8 supplied broader and alternative protection. The use claims added litigation leverage against products labeled for emesis or other specified conditions.
The main potential validity issues for a patent of this type would have included:
- Prior-art indazole carboxamides;
- Obviousness of combining the indazole nucleus with the azabicyclic amine;
- Written-description support for the full Markush genus;
- Enablement across the large R1 and R4 substituent ranges;
- Stereochemical characterization of the endo isomer;
- Salt and polymorph distinctions; and
- Utility support for the psychiatric and neurological indications.
Those issues mattered during the patent term. They have no current effect on freedom to operate under the expired patent.
What formulation patents protected granisetron products?
The ’808 patent is primarily a compound and therapeutic-use patent. It does not provide a detailed modern formulation platform comparable to extended-release, transdermal, orally disintegrating, or long-acting delivery patents.
Potential later protection could have covered:
- Injectable compositions;
- Tablet formulations;
- Dosage strengths;
- Stabilized aqueous preparations;
- Transdermal delivery;
- Specific crystalline or salt forms;
- Manufacturing processes; and
- Combination antiemetic regimens.
A later patent would require independent analysis of its claims, expiration date, terminal disclaimers, and Orange Book listing. The existence of a later formulation patent would not revive the expired composition patent.
How does granisetron compare with competing 5-HT3 antagonists?
| Product |
Active ingredient |
Patent position |
Current competitive status |
| Kytril |
Granisetron |
Original compound patent expired |
Generic competition |
| Zofran |
Ondansetron |
Original compound and key exclusivities expired |
Broad generic competition |
| Anzemet |
Dolasetron |
Original exclusivity expired |
Limited commercial relevance |
| Aloxi |
Palonosetron |
Later-generation product with longer persistence and distinct patent estate |
Branded and generic competition varies by form |
| Tropisetron products |
Tropisetron |
Foreign-market relevance greater than U.S. relevance |
Limited U.S. presence |
Granisetron competes pharmacologically with ondansetron and other 5-HT3 antagonists. Its commercial differentiation has depended on dosing convenience, clinical positioning, injectable availability, hospital use, and payer pricing rather than a continuing patent barrier.
What generic launch risks remain?
For ordinary immediate-release granisetron tablets or injectable products, the expired ’808 patent presents no current U.S. launch risk. Remaining risks are more likely to arise from:
- A separate unexpired formulation patent;
- A listed method-of-use patent with a relevant label;
- Manufacturing or process patents;
- Product-specific regulatory deficiencies;
- Labeling or induced-infringement issues;
- Drug-supply and manufacturing controls; and
- Trademark or trade-dress restrictions involving Kytril.
A generic applicant could pursue a section 505(j) ANDA for a therapeutically equivalent granisetron product. The applicant would still need to satisfy pharmaceutical equivalence, bioequivalence, chemistry, manufacturing and controls, stability, labeling, and facility requirements.
What manufacturing and IP barriers remain after expiration?
Patent expiration does not remove manufacturing barriers. Granisetron hydrochloride API production requires control of:
- Regioselective and stereoselective synthesis;
- Endo-isomer purity;
- Residual solvents and impurities;
- Salt formation;
- Particle-size distribution;
- Injectable sterility where applicable; and
- Stability of the finished dosage form.
Those technical requirements are regulatory and commercial barriers, not continuing rights under the ’808 patent. A process patent could still matter if it claims a specific route, catalyst, crystallization method, impurity-control process, or formulation operation. Freedom-to-operate analysis therefore must examine later process and product patents separately.
What is the current commercial exposure?
The principal commercial exposure associated with the patent was the branded Kytril franchise. Once the patent expired, the market moved from compound-level exclusivity to generic price competition. The patent no longer protects branded revenue.
Revenue exposure from the original patent was highest in the period before generic entry, particularly for:
- Oncology supportive care;
- Chemotherapy-induced nausea and vomiting;
- Postoperative nausea and vomiting;
- Hospital injectable use; and
- Oral tablet maintenance or delayed-emesis treatment.
Current revenue analysis should focus on product-level sales, generic erosion, reimbursement, shortage conditions, and any newer delivery systems. Patent expiry alone does not quantify brand revenue loss, but it removes the legal basis for excluding competing granisetron products.
Key Takeaways
- U.S. Patent 4,886,808 is the foundational U.S. granisetron patent.
- Claim 10 specifically covers granisetron monohydrochloride.
- Claim 1 covers a broader genus of indazole-3-carboxamide compounds.
- Claims 8 and 10 provide direct protection for the commercially important granisetron structure and salt.
- Claims 11 through 20 cover compositions and therapeutic methods, including emesis treatment.
- The patent issued December 12, 1989 and expired December 12, 2006.
- The patent no longer blocks generic granisetron manufacture, sale, or ANDA approval.
- Granisetron is a small molecule, so biosimilar rules do not apply.
- Any current launch risk must arise from later formulation, process, method-of-use, or product-specific patents.
- The patent estate was strong during its term because it combined genus, species, stereochemical, salt, composition, and method claims.
FAQs
Is U.S. Patent 4,886,808 still enforceable?
No. The patent expired on December 12, 2006 under the applicable 17-year patent term.
Does claim 10 cover Kytril?
Yes. Claim 10 covers N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methylindazole-3-carboxamide monohydrochloride, the active salt form of granisetron used in Kytril.
Can a generic company manufacture granisetron without licensing the ’808 patent?
Yes, because the patent has expired. A company must still satisfy FDA approval, quality, manufacturing, labeling and bioequivalence requirements.
Does the patent cover ondansetron or palonosetron?
No. The claims are directed to indazole carboxamides containing the specified azabicyclic amine structures. Ondansetron and palonosetron have different chemical structures and separate patent histories.
Could a later granisetron formulation patent still block launch?
Yes. Expiration of the ’808 patent does not eliminate a separate unexpired patent covering a formulation, dosage form, manufacturing process, crystalline form, or method of use.
References
-
U.S. Patent No. 4,886,808. (1989). Indazole derivatives. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (n.d.). Kytril (granisetron hydrochloride) prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. FDA.
-
United States Patent and Trademark Office. (n.d.). Manual of Patent Examining Procedure: Patent term and patent term adjustment. USPTO.
